Literature DB >> 25098269

FAK in cancer: mechanistic findings and clinical applications.

Florian J Sulzmaier1, Christine Jean1, David D Schlaepfer1.   

Abstract

Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. FAK promotes tumour progression and metastasis through effects on cancer cells, as well as stromal cells of the tumour microenvironment. The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal. Small molecule FAK inhibitors decrease tumour growth and metastasis in several preclinical models and have initial clinical activity in patients with limited adverse events. In this Review, we discuss FAK signalling effects on both tumour and stromal cell biology that provide rationale and support for future therapeutic opportunities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098269      PMCID: PMC4365862          DOI: 10.1038/nrc3792

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  139 in total

1.  Focal adhesion kinase inhibitors are potent anti-angiogenic agents.

Authors:  Miguel A Cabrita; Laura M Jones; Jennifer L Quizi; Luc A Sabourin; Bruce C McKay; Christina L Addison
Journal:  Mol Oncol       Date:  2011-10-20       Impact factor: 6.603

2.  Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2.

Authors:  James Lulo; Satoru Yuzawa; Joseph Schlessinger
Journal:  Biochem Biophys Res Commun       Date:  2009-04-07       Impact factor: 3.575

3.  Loss of Scar/WAVE complex promotes N-WASP- and FAK-dependent invasion.

Authors:  Haoran Tang; Ang Li; Jing Bi; Douwe M Veltman; Tobias Zech; Heather J Spence; Xinzi Yu; Paul Timpson; Robert H Insall; Margaret C Frame; Laura M Machesky
Journal:  Curr Biol       Date:  2012-12-27       Impact factor: 10.834

4.  Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors.

Authors:  Timo Heinrich; Jeyaprakashnarayanan Seenisamy; Lourdusamy Emmanuvel; Santosh S Kulkarni; Jörg Bomke; Felix Rohdich; Hartmut Greiner; Christina Esdar; Mireille Krier; Ulrich Grädler; Djordje Musil
Journal:  J Med Chem       Date:  2013-01-22       Impact factor: 7.446

5.  Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo.

Authors:  Huaping Fan; Xiaofeng Zhao; Shaogang Sun; Ming Luo; Jun-Lin Guan
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

Review 6.  Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Authors:  William G Cance; Elena Kurenova; Timothy Marlowe; Vita Golubovskaya
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

7.  Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.

Authors:  Cedo M Bagi; James Christensen; Darrel P Cohen; Walter G Roberts; Dean Wilkie; Terri Swanson; Theresa Tuthill; Catharine J Andresen
Journal:  Cancer Biol Ther       Date:  2009-05       Impact factor: 4.742

8.  Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.

Authors:  S K Mitra; S-T Lim; A Chi; D D Schlaepfer
Journal:  Oncogene       Date:  2006-03-20       Impact factor: 9.867

9.  Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis.

Authors:  Tang-Long Shen; Ann Y-J Park; Ana Alcaraz; Xu Peng; Ihnkyung Jang; Pandelakis Koni; Richard A Flavell; Hua Gu; Jun-Lin Guan
Journal:  J Cell Biol       Date:  2005-06-20       Impact factor: 10.539

10.  PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility.

Authors:  Yangmi Lim; Ssang-Taek Lim; Alok Tomar; Margaret Gardel; Joie A Bernard-Trifilo; Xiao Lei Chen; Sean A Uryu; Rafaela Canete-Soler; Jinbin Zhai; Hong Lin; William W Schlaepfer; Perihan Nalbant; Gary Bokoch; Dusko Ilic; Clare Waterman-Storer; David D Schlaepfer
Journal:  J Cell Biol       Date:  2008-01-14       Impact factor: 10.539

View more
  471 in total

1.  Triptolide Inhibits Lung Cancer Cell Migration, Invasion, and Metastasis.

Authors:  Theresa A Reno; Jae Y Kim; Dan J Raz
Journal:  Ann Thorac Surg       Date:  2015-08-20       Impact factor: 4.330

2.  Integr(at)in(g) EGFR therapy in HNSCC.

Authors:  Valentina D'Amato; Roberta Rosa; Roberto Bianco
Journal:  Ann Transl Med       Date:  2015-12

3.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

4.  FAK Promotes Osteoblast Progenitor Cell Proliferation and Differentiation by Enhancing Wnt Signaling.

Authors:  Chunhui Sun; Hebao Yuan; Li Wang; Xiaoxi Wei; Linford Williams; Paul H Krebsbach; Jun-Lin Guan; Fei Liu
Journal:  J Bone Miner Res       Date:  2016-10-24       Impact factor: 6.741

5.  Upregulation of CPNE3 suppresses invasion, migration and proliferation of glioblastoma cells through FAK pathway inactivation.

Authors:  Dijian Shi; Bo Lin; Jun Lai; Kaipeng Li; Yimo Feng
Journal:  J Mol Histol       Date:  2021-03-16       Impact factor: 2.611

6.  The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation.

Authors:  Alex Kiepas; Elena Voorand; Julien Senecal; Ryuhjin Ahn; Matthew G Annis; Kévin Jacquet; George Tali; Nicolas Bisson; Josie Ursini-Siegel; Peter M Siegel; Claire M Brown
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

7.  FAK Promotes Early Osteoprogenitor Cell Proliferation by Enhancing mTORC1 Signaling.

Authors:  Shuqun Qi; Xiumei Sun; Han Kyoung Choi; Jinfeng Yao; Li Wang; Guomin Wu; Yun He; Jian Pan; Jun-Lin Guan; Fei Liu
Journal:  J Bone Miner Res       Date:  2020-06-05       Impact factor: 6.741

8.  miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Authors:  Ying Zhou; Jason Dang; Kung-Yen Chang; Edwin Yau; Pedro Aza-Blanc; Jorge Moscat; Tariq M Rana
Journal:  Cancer Res       Date:  2016-10-01       Impact factor: 12.701

9.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

Review 10.  Physical traits of cancer.

Authors:  Hadi T Nia; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2020-10-30       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.